BRIAN BROWN: Open Payments
NPI 1477082337 · VISALIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,050 in 98 payments from 28 companies in 2025. Trend: 2023 $2,858 · 2024 $2,532 · 2025 $2,050
Food & beverage: $2,050
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 8 | $256 |
| Novo Nordisk Inc | 14 | $239 |
| ABIOMED | 4 | $191 |
| ABBVIE INC. | 8 | $157 |
| Lilly USA, LLC | 12 | $139 |
| Axsome Therapeutics, Inc. | 5 | $113 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Verity Pharmaceuticals Inc. | 4 | $73 |
| PFIZER INC. | 3 | $71 |
| Merck Sharp & Dohme LLC | 3 | $66 |
Products named: RECORLEV, REXULTI, MOUNJARO, Ozempic, Auvelity, Wegovy, VRAYLAR, Tlando.
Industry payments across CA — which companies pay providers there.
